Pharmaron Beijing Co (STU:17Q1) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:17Q1 Pharmaron Beijing Co Ltd STU:17Q1
92 GF Score
Price €2.48
GF Value €2.26
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Pharmaron Beijing Co Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

STU:17Q1
92GF Score
Pharmaron Beijing Co Ltd STU:17Q1
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pharmaron Beijing Co (STU:17Q1) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued. The current stock price of €2.48 is trading 9.7% above its estimated GF Value™ of €2.26. GuruFocus considers Pharmaron Beijing Co to be Fairly Valued.

Key valuation signals for STU:17Q1:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €2.26 vs. price of €2.48 (9.7% above fair value)
  • GF Score™: 92/100 with 8 warning signs

No single metric tells the full story. See the STU:17Q1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharmaron Beijing Co Business Description

Address 6 Tai-He Road, 8th Floor, Block 1, Beijing Economic Technological Development Area, Beijing, CHN, 100176
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
92GF Score

Get the complete analysis for STU:17Q1

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.48
Price
€2.26
GF Value